Goserelin injection of sustained-release implants nursing clinic.docVIP

 PAGE \* MERGEFORMAT 6 Goserelin injection of sustained-release implants nursing clinic [Keywords:] Reynolds; abdominal subcutaneous; Mission Sustained-release implant goserelin acetate (trade Mingnuoleide) is an injection of luteinizing hormone releasing hormone analogue (LHRHa). It can inhibit the secretion of sex hormones (testosterone and estradiol), which the hormone sensitive tumors to shrink. is a long-acting hormonal preparations, reaction time can be maintained for 1 month. now used extensively for prostate cancer patients, especially in advanced prostate cancer treatment was available [1]. in recent years is treatment of severe endometriosis of the new drugs, play a relieve symptoms before surgery, including pain relief and to reduce the uterine size and number of balloon injury. Postoperative nore can eliminate residual disease and prevent recurrence. our hospital since 2009 The patient injection room in the two cases of injection of more than 200 people, now experience the following. 1 character and the amount of drugs, usage Nuolei De gradually in the body is a biodegradable polymer sustained release implant. Sterile, white or milky white columns, placed in a syringe, single dose. In two sizes: round Ge acetate Ruilin 3.6 mg / support given over 28 days; goserelin acetate 7.2 mg / support given over 56 days. subcutaneously in the abdominal wall. 2 adverse reactions Rash, flushing, and male patients seen decreased libido, breast swelling and occasionally, the early treatment of prostate cancer patients may have temporarily increased bone pain, urinary tract obstruction and symptoms of spinal cord compression can be seen in other cases. Women with visible flushing, sweating, decreased libido, headache , emotional changes, such as depression, vaginal dryness, and breast size changes, the early treatment of breast cancer patients may exacerbate symptoms. 3 Care 3.1 Environment for injection were required to expose the entire abd